Clinical Trial Update: Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy [Phase 2]

View source ↗

Summary

This is a completed Phase 2 trial evaluating tivantinib (ARQ 197) in patients with unresectable hepatocellular carcinoma after failure of one prior systemic the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ARQ 197 (tivantinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Unresectable Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED